Lamisilonce

Terbinafine, the active ingredient in Lamisilonce, is a allylamine antifungal presented as a topical formulation for topical use. It treats dermatophyte skin infections such as athlete's foot, ringworm, and jock itch in adults and children.

GNH USA supplies Lamisilonce as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Terbinafine is used to treat fungal skin infections caused by dermatophytes.

- Tinea pedis: relief of itching and eradication of the causative fungus. - Tinea corporis: clearance of ring‑shaped lesions and prevention of spread. - Tinea cruris: reduction of inflammation and elimination of the infection.

Common side effects are usually mild and limited to the application site.

Common Side Effects: - Itching: mild to moderate sensation at the site of application. - Burning: transient heat sensation during or after use. - Redness: localized erythema. - Dryness or scaling: mild skin desquamation.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of swelling, difficulty breathing. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin detachment. - Severe skin rash: widespread erythematous eruption. - Hepatic dysfunction: abnormal liver enzymes. - Contact dermatitis: intense local inflammation.

Before using Lamisilonce, consider the following precautions.

- Apply to intact skin only: avoid broken or inflamed areas. - Avoid use on mucous membranes: do not apply to eyes, nose, or mouth. - Limit duration: follow prescriber instructions, typically up to four weeks. - Monitor for allergic reactions: discontinue if a severe rash or swelling develops. - Store at room temperature: keep in the original container, protect from moisture and light.

Terbinafine may interact with other medications or topical agents.

Major Interactions (Avoid): - Concurrent systemic terbinafine: may increase systemic exposure and risk of toxicity. - Oral antifungals metabolized by CYP2D6: potential additive hepatic effects.

Moderate Interactions (Monitor Closely): - Use with other topical irritants (e.g., corticosteroids): may increase skin irritation. - Use with occlusive dressings: may enhance percutaneous absorption. - Concurrent photosensitizing agents: may increase risk of sunburn.